Insights & Resources | Pfizer CentreOne

Considerations for Migrating a Drug Product Presentation from Vial to Pre-Filled Syringe

This whitepaper outlines the benefits of PFS transfer, the differences between glass and PFS devices, and the key engineering processes required to successfully carry out this process.

Three Key CDMO Trends for 2022 and Beyond

What are the key CDMO trends pharmaceutical companies must prepare for in 2022 and beyond? This blog explains our top 3. Read more here.

Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms

In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.

Placing Drug Strategies on a Solid Foundation for Success

Our whitepaper explores current market dynamics and the latest drug development trends driving these strategic outsourcing decisions.

Migrating A Drug Product Presentation From Vial To Prefilled Syringe - On Drug Delivery

This article explores some of the leading engineering activities that are necessary for successful PFS transfers and the benefits they offer.

Understanding the Challenges of Highly Potent Actives - International Pharmaceutical Industry

From managing health and safety risks to effective potency classifications, there are many challenges pharmaceutical companies face when using highly potent active pharmaceutical ingredients (HPAPIs) for the first time. This article explores these challenges in-depth and how they can be overcome.

Pfizer CenterOne’s Enviero® receives first EU authorization as part of ESTIMA® (progesterone) product approval.

Pfizer CentreOne’s green-chemistry progesterone API, Enviero®, has been approved for use in the EU for the first time in a drug product manufactured by French pharmaceutical company, Effik.

Sterile Injectables Supply on Demand

Demand for supplies of materials for sterile injectable production, such as glass vials, filters, and stoppers has soared, which has resulted in shortages that have impacted the manufacturing of other drug products. In addition, there have been increased quality concerns associated with these high demand materials.

De-risking API & Intermediate Supply in a Crisis

Pharmaceutical supply chains have been consistently growing in complexity for many years. For some products, their supply chains are so complex and globalized that they start in and return to Asia after circumnavigating the globe several times.

Highly Potent Oral Solids: Top Considerations

Understanding product classification and the heightened complexity of HPAPI drug substance transfer and manufacturing is critical. Developers are increasingly working with CDMOs to commercialize their HPAPIs. Kieran Coffey, Technical Services Lead at Pfizer CentreOne, discusses these key considerations

Experience the Art of Science - Debbie Lemons's story

In this instalment of our ‘Experience the Art of Science’ blog series, we meet Debbie Lemons, Senior Regulatory Compliance External Lead Auditor at our Rocky Mount facility.

Building More Resilient API Supply Chains

Safe, secure and reliable supply lines for key medicines is one of pharma's top priorities. However, as recent reports about shortages of active pharmaceutical ingredients (APIs) impacting on the supply of key medicines show, there are lessons to be learned to ensure optimum supply chain security.